1 序文
2 範囲と方法論
2.1 本調査の目的
2.2 利害関係者
2.3 データソース
2.3.1 一次ソース
2.3.2 二次ソース
2.4 市場推定
2.4.1 ボトムアップアプローチ
2.4.2 トップダウンアプローチ
2.5 予測方法論
3 エグゼクティブサマリー
4 はじめに
4.1 概要
4.2 主な業界トレンド
5 世界の再生医療市場
5.1 市場概要
5.2 市場実績
5.3 COVID-19 の影響
5.4 市場予測
6 種類別市場内訳
6.1 幹細胞治療
6.1.1 市場動向
6.1.2 市場予測
6.2 生体材料
6.2.1 市場動向
6.2.2 市場予測
6.3 組織工学
6.3.1 市場動向
6.3.2 市場予測
6.4 その他
6.4.1 市場動向
6.4.2 市場予測
7 用途別市場
7.1 骨移植代替品
7.1.1 市場動向
7.1.2 市場予測
7.2 骨関節疾患
7.2.1 市場動向
7.2.2 市場予測
7.3 皮膚科
7.3.1 市場動向
7.3.2 市場予測
7.4 循環器科
7.4.1 市場動向
7.4.2 市場予測
7.5 中枢神経系
7.5.1 市場動向
7.5.2 市場予測
7.6 その他
7.6.1 市場動向
7.6.2 市場予測
8 エンドユーザー別市場内訳
8.1 病院
8.1.1 市場動向
8.1.2 市場予測
8.2 専門クリニック
8.2.1 市場動向
8.2.2 市場予測
8.3 その他
8.3.1 市場動向
8.3.2 市場予測
9 地域別市場
9.1 北米
9.1.1 米国
9.1.1.1 市場動向
9.1.1.2 市場予測
9.1.2 カナダ
9.1.2.1 市場動向
9.1.2.2 市場予測
9.2 アジア太平洋地域
9.2.1 中国
9.2.1.1 市場動向
9.2.1.2 市場予測
9.2.2 日本
9.2.2.1 市場動向
9.2.2.2 市場予測
9.2.3 インド
9.2.3.1 市場動向
9.2.3.2 市場予測
9.2.4 韓国
9.2.4.1 市場動向
9.2.4.2 市場予測
9.2.5 オーストラリア
9.2.5.1 市場動向
9.2.5.2 市場予測
9.2.6 インドネシア
9.2.6.1 市場動向
9.2.6.2 市場予測
9.2.7 その他
9.2.7.1 市場動向
9.2.7.2 市場予測
9.3 ヨーロッパ
9.3.1 ドイツ
9.3.1.1 市場動向
9.3.1.2 市場予測
9.3.2 フランス
9.3.2.1 市場動向
9.3.2.2 市場予測
9.3.3 英国
9.3.3.1 市場動向
9.3.3.2 市場予測
9.3.4 イタリア
9.3.4.1 市場動向
9.3.4.2 市場予測
9.3.5 スペイン
9.3.5.1 市場動向
9.3.5.2 市場予測
9.3.6 ロシア
9.3.6.1 市場動向
9.3.6.2 市場予測
9.3.7 その他
9.3.7.1 市場動向
9.3.7.2 市場予測
9.4 ラテンアメリカ
9.4.1 ブラジル
9.4.1.1 市場動向
9.4.1.2 市場予測
9.4.2 メキシコ
9.4.2.1 市場動向
9.4.2.2 市場予測
9.4.3 その他
9.4.3.1 市場動向
9.4.3.2 市場予測
9.5 中東およびアフリカ
9.5.1 市場動向
9.5.2 国別の市場内訳
9.5.3 市場予測
10 SWOT分析
10.1 概要
10.2 強み
10.3 弱み
10.4 機会
10.5 脅威
11 価値連鎖分析
12 ポーターのファイブフォース分析
12.1 概要
12.2 買い手の交渉力
12.3 売り手の交渉力
12.4 競争の度合い
12.5 新規参入の脅威
12.6 代替品の脅威
13 価格分析
14 競合状況
14.1 市場構造
14.2 主要企業
14.3 主要企業のプロフィール
Allergan PLC (AbbVie Inc.)
Amgen Inc
Baxter International Inc
BD (Becton
Dickinson and Company)
Integra Lifesciences Holdings Corporation
Medtronic plc
Mimedx Group Inc
Novartis AG
Osiris Therapeutics Inc. (Smith & Nephew plc)
Thermo Fisher Scientific Inc

The global regenerative medicine market size reached USD 26.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 130.4 Billion by 2033, exhibiting a growth rate (CAGR) of 19.15% during 2025-2033. The increasing transplant rejection concerns, the rising demand for regenerative therapies for orthopedic conditions, the growing dental regeneration, and the escalating medicine use in wound healing are some of the factors propelling the market growth.

Regenerative medicine represents a promising biomedical science field focused on restoring damaged tissues and organs. It harnesses laboratory-cultivated stem cells, safely transplanted into the body to stimulate the regeneration of bones, cartilage, blood vessels, and vital organs. This multidimensional approach encompasses cellular and acellular regenerative therapies, including immunomodulation and tissue engineering techniques. Beyond tissue repair, regenerative medicine holds immense potential in treating chronic ailments like Alzheimer's, Parkinson's, cardiovascular diseases (CVDs), osteoporosis, and spinal cord injuries. As research advances, it offers hope for transformative treatments that could significantly improve patients' lives and healthcare outcomes.

The global market is majorly driven by the increasing aging population. In line with this, the rising prevalence of chronic diseases such as diabetes, heart disease, and osteoarthritis is significantly contributing to the market growth. Furthermore, the growing research in stem cell therapies and genetic engineering drives innovation in regenerative medicine. The escalating use of stem cells and other cell-based therapies for tissue regeneration and repair is also catalyzing the market. Moreover, the funding and regulatory support for regenerative medicine research and development are creating a positive outlook for the market. Besides, the advancements in biotechnology enable more precise and effective regenerative therapies, bolstering the market. Additionally, the increasing awareness among patients about regenerative treatment options is providing a boost to the market.

Regenerative Medicine Market Trends/Drivers:
Increasing product demand in cancer treatment

The increasing product demand in cancer treatment is catalyzing the market. Cancer, characterized by uncontrolled cell growth, often leads to tissue damage, which can be addressed through regenerative therapies. Regenerative medicine allows for the development of targeted therapies that can repair damaged tissues caused by cancer or side effects of treatments like chemotherapy. It aims to minimize traditional cancer treatment's debilitating side effects, enhancing patients' overall quality of life. These techniques can help modulate the tumor microenvironment, potentially inhibiting cancer progression. It also complements emerging cancer immunotherapies by repairing immune cells or tissues affected during treatment. Robust research and clinical trials explore the potential of regenerative therapies in various cancer types, fostering market growth. The potential for regenerative therapies to revolutionize cancer treatment attracts investment in research and development. The rising prevalence of cancer and the pursuit of more effective, patient-friendly treatments fuel the demand for regenerative medicine in cancer care, contributing significantly to the market's expansion.

Rapid advancements in immunotherapy

Rapid advancements in immunotherapy are propelling the market. Immunotherapy, a subset of regenerative medicine, harnesses the body's immune system to fight diseases, including cancer and autoimmune disorders. Immunotherapies like CAR-T cell therapy and immune checkpoint inhibitors have revolutionized cancer treatment by enhancing the body's ability to recognize and combat cancer cells. Advances in immunotherapy enable more personalized treatment approaches, aligning with the trend toward precision medicine. They often have fewer severe side effects than traditional treatments like chemotherapy and radiation therapy, improving patient outcomes. Researchers explore combining immunotherapies with regenerative approaches to enhance treatment efficacy, expanding the scope of regenerative medicine. Robust clinical trials and research initiatives focus on optimizing immunotherapies, driving innovation in the field. Immunotherapies are being investigated for applications beyond cancer, including autoimmune diseases, infectious diseases, and organ transplantation. The potential of immunotherapy to transform disease management attracts substantial investments in research and development. Increasing patient advocacy and awareness of immunotherapies contribute to their adoption and market growth.

Widespread product applications in cosmetic surgery and aesthetics

The widespread product applications in cosmetic surgery and aesthetics are a driving force behind the growth of this market segment. Regenerative therapies, including adipose-derived stem cell treatments, are used for natural tissue augmentation in procedures like breast reconstruction and facial rejuvenation. They offer innovative anti-aging treatments, such as platelet-rich plasma (PRP) therapy and stem cell-based interventions, appealing to individuals seeking youthful appearances. Regenerative techniques are employed to minimize the appearance of scars resulting from surgeries, accidents, or injuries, enhancing aesthetic outcomes. Stem cell-based regenerative therapies are utilized for hair restoration, addressing hair loss and baldness concerns. The rise of minimally invasive aesthetic regenerative procedures appeals to patients seeking shorter recovery times and reduced scarring. The demand for regenerative aesthetics continues to grow, attracting investments and innovations in the field. High patient satisfaction rates and positive outcomes in regenerative aesthetic procedures drive word-of-mouth referrals and market expansion.

Regenerative Medicine Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global regenerative medicine market report, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on type, application, and end user.

Breakup by Type:

Stem Cell Therapy
Biomaterial
Tissue Engineering
Others

Stem cell therapy dominates the market

The report has provided a detailed breakup and analysis of the market based on the type. This includes stem cell therapy, biomaterial, tissue engineering, and others. According to the report, stem cell therapy represented the largest segment.

Stem cell therapy harnesses the unique regenerative properties of stem cells to repair and replace damaged or dysfunctional tissues and organs. It offers diverse therapeutic applications, including orthopedics, cardiology, neurology, and oncology. This versatility attracts investment and research, expanding its market presence. Clinical trials and case studies demonstrate the effectiveness of stem cell therapies in treating previously incurable conditions, boosting patient and physician confidence. With the global population aging, there's an increasing prevalence of age-related diseases and degenerative conditions, driving demand for regenerative treatments.

Furthermore, the regulatory bodies recognize stem cell therapies' potential, resulting in streamlined approvals and guidelines, further encouraging market growth. Patients seeking alternatives to conventional treatments are turning to stem cell therapies for better outcomes and reduced side effects. The potential of stem cell therapies attracts investments, fostering research and development and expanding accessibility. Advances in stem cell isolation, culturing, and delivery methods improve treatment efficacy, expanding their applications. Stem cell therapy providers are expanding their reach globally, making these treatments available to a wider patient population.

Breakup by Application:

Bone Graft Substitutes
Osteoarticular Diseases
Dermatology
Cardiovascular
Central Nervous System
Others

Dermatology dominates the market

The report has provided a detailed breakup and analysis of the market based on the application. This includes bone graft substitutes, osteoarticular diseases, dermatology, cardiovascular, central nervous system, and others. According to the report, dermatology represented the largest segment.

Dermatology is a vital application within regenerative medicine, focusing on the restoration and regeneration of skin tissues. It addresses a wide spectrum of dermatological concerns, ranging from scar reduction and wound healing to treating skin disorders and aging-related skin conditions.

Regenerative approaches in dermatology include using stem cells, growth factors, and tissue engineering techniques, offering patients innovative and minimally invasive solutions for achieving healthier, more youthful, and blemish-free skin. This segment is gaining traction due to the growing demand for cosmetic and aesthetic enhancements and the need for effective treatments for various skin ailments, ultimately contributing to the overall growth of the regenerative medicine market.

Breakup by End User:

Hospitals
Specialty Clinics
Others

Hospitals dominate the market

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, specialty clinics, and others. According to the report, hospitals represented the largest segment.

Hospitals serve as prominent end users within the regenerative medicine market, playing a pivotal role in the adoption and growth of regenerative therapies. They serve as hubs for advanced medical care and are integral for several reasons. Hospitals provide the infrastructure and expertise necessary for conducting complex regenerative procedures, such as organ transplants and stem cell therapies, ensuring patient safety and optimal outcomes. They also facilitate clinical trials and research initiatives, allowing for the development and testing innovative regenerative treatments.

Furthermore, hospitals are key in delivering regenerative therapies to patients, especially acute injuries, chronic diseases, or conditions requiring specialized medical attention. As healthcare institutions embrace regenerative medicine, hospitals remain central in its expansion, offering hope and cutting-edge treatments to a diverse patient population.

Breakup by Region:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

North America exhibits a clear dominance, accounting for the largest market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America represents a significant region in the regenerative medicine market, driving growth through several key factors. The region's advanced healthcare infrastructure, robust research and development capabilities, and high healthcare expenditure contribute to the adoption of regenerative therapies. It is home to numerous renowned research institutions, biotechnology companies, and academic centers specializing in regenerative medicine, fostering innovation and clinical advancements.

Regulatory support and well-defined approval processes in countries like the United States accelerate the introduction of regenerative treatments to the market. A growing aging population with age-related conditions also fuels the demand for regenerative solutions. Moreover, a strong focus on addressing chronic diseases, sports injuries, and aesthetic concerns further propels the use of regenerative therapies in North America. These factors collectively position North America as a prominent growth driver in the regenerative medicine sector.

Competitive Landscape:
Top companies are strengthening the market through innovation, strategic partnerships, and extensive research. They invest heavily in research and development, pushing the boundaries of regenerative medicine, uncovering new therapies, and expanding treatment options. They conduct large-scale clinical trials to demonstrate the safety and efficacy of regenerative therapies, gaining regulatory approvals and boosting market confidence. Top companies develop a diverse portfolio of regenerative products, catering to various medical conditions and applications, from orthopedics to oncology. These companies expand globally, ensuring wider access to their therapies and increasing market reach. Partnerships with research institutions, healthcare providers, and pharmaceutical companies facilitate knowledge sharing and the development of novel therapies. They navigate complex regulatory landscapes, ensuring their therapies meet stringent safety and quality standards instilling trust in healthcare professionals and patients. Top companies engage in patient advocacy and education, raising awareness about the benefits of regenerative medicine, thus driving demand. Their track record of success attracts investments, enabling further research and development of groundbreaking therapies.

The report has provided a comprehensive analysis of the competitive landscape in the regenerative medicine market. Detailed profiles of all major companies have also been provided.

Allergan PLC (AbbVie Inc.)
Amgen Inc.
Baxter International Inc.
BD (Becton, Dickinson and Company)
Integra Lifesciences Holdings Corporation
Medtronic plc
Mimedx Group Inc.
Novartis AG
Osiris Therapeutics Inc. (Smith & Nephew plc)
Thermo Fisher Scientific Inc

Key Questions Answered in This Report:
How has the global regenerative medicine market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global regenerative medicine market?
What is the impact of each driver, restraint, and opportunity on the global regenerative medicine market?
What are the key regional markets?
Which countries represent the most attractive regenerative medicine market?
What is the breakup of the market based on the type?
Which is the most attractive type in the regenerative medicine market?
What is the breakup of the market based on the application?
Which is the most attractive application in the regenerative medicine market?
What is the breakup of the market based on the end user?
Which is the most attractive end user in the regenerative medicine market?
What is the competitive structure of the global regenerative medicine market?
Who are the key players/companies in the global regenerative medicine market?

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Regenerative Medicine Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Stem Cell Therapy
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Biomaterial
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Tissue Engineering
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Application
7.1 Bone Graft Substitutes
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Osteoarticular Diseases
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Dermatology
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Cardiovascular
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Central Nervous System
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Others
7.6.1 Market Trends
7.6.2 Market Forecast
8 Market Breakup by End User
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Specialty Clinics
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Allergan PLC (AbbVie Inc.)
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Amgen Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Baxter International Inc.
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 BD (Becton, Dickinson and Company)
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Integra Lifesciences Holdings Corporation
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Medtronic Plc
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Mimedx Group Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.8 Novartis AG
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Osiris Therapeutics Inc. (Smith & Nephew plc)
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10 Thermo Fisher Scientific Inc.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis

*** 再生医療の世界市場に関するよくある質問(FAQ) ***

・再生医療の世界市場規模は？
→IMARC社は2024年の再生医療の世界市場規模を267億米ドルと推定しています。

・再生医療の世界市場予測は？
→IMARC社は2033年の再生医療の世界市場規模を1304億米ドルと予測しています。

・再生医療市場の成長率は？
→IMARC社は再生医療の世界市場が2025年～2033年に年平均19.2%成長すると展望しています。

・世界の再生医療市場における主要プレイヤーは？
→「Allergan PLC (AbbVie Inc.), Amgen Inc., Baxter International Inc., BD (Becton, Dickinson and Company), Integra Lifesciences Holdings Corporation, Medtronic plc, Mimedx Group Inc., Novartis AG, Osiris Therapeutics Inc. (Smith & Nephew plc), Thermo Fisher Scientific Inc.など ...」を再生医療市場のグローバル主要プレイヤーとして判断しています。

※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/